Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep;472(9):2728-34.
doi: 10.1007/s11999-013-2963-1.

Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails

Affiliations

Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails

Kenneth A Egol et al. Clin Orthop Relat Res. 2014 Sep.

Abstract

Background: Bisphosphonate therapy for osteoporosis has been associated with atypical femoral fractures. To date, there have been few reports in the literature regarding the preoperative and postoperative courses of patients who have sustained bisphosphonate-associated complete atypical femur fractures.

Objectives/purposes: The purposes of this study were to (1) characterize the preoperative course of patients who eventually presented with bisphosphonate-associated complete atypical femur fractures (duration of bisphosphonate treatment, pain history, risk of converting a nondisplaced fracture to a complete fracture); (2) evaluate the percentage of patients who achieved radiographic union of those fractures after treatment; and (3) determine the patients' recovery of function using the Short Musculoskeletal Functional Assessment.

Methods: Thirty-three patients with 41 atypical, low-energy femur fractures associated with ≥ 5 years of bisphosphonate use were treated with intramedullary nailing between 2004 and 2011 at one center. The main outcome measurements were Short Musculoskeletal Functional Assessment for function and radiographic evaluation for fracture healing. Patients had been treated with bisphosphonates for an average of 8.8 years (range, 5-20 years) before presentation.

Results: Patients reported a mean of 6 months of pain before presentation (range, 1-8 months). Sixty-six percent of patients with surgically treated complete fractures became pain-free and 98% were radiographically healed by 12 months. Sixty-four percent of patients who underwent intramedullary nailing reported a functional return to baseline within 1 year. Patients who reported major functional limitations at latest followup listed pain and apprehension as the major causes of their limitation.

Conclusions: Patients with surgically treated bisphosphonate-associated complete femur fractures achieved generally reliable although delayed fracture healing if malaligned, and nearly two-thirds of patients returned to self-reported baseline function within 1 year.

Level of evidence: Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

PubMed Disclaimer

Figures

Fig. 1A–C
Fig. 1A–C
(A) The AP radiograph at presentation of a 78-year-old woman treated with bisphosphonate therapy for 15 years shows radiographic characteristics of a complete bisphosphonate-associated fracture. (B) The AP radiograph of the same patient at 2 months status postintramedullary fixation shows early signs of healing. (C) The AP radiograph at 6 months status postfixation shows a healed fracture.
Fig. 2
Fig. 2
The flow diagram of patients shows how the final study cohort was determined from our registry of bisphosphonate-associated femoral fracture cases.
Fig. 3A–B
Fig. 3A–B
Radiographs of the patient who went on to nonunion. (A) In this radiograph, the distal locking bolt was placed through a slot instead of a hole, which allowed for varus displacement at the fracture site and nonunion. (B) The patient went on to achieve fracture union after revision surgery.

Similar articles

Cited by

References

    1. Audran M, Cortet B, Thomas T. What do we know about atypical femoral fractures? Insights and enigmas. Joint Bone Spine. 2011;78:568–571. doi: 10.1016/j.jbspin.2011.03.015. - DOI - PubMed
    1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541. doi: 10.1016/S0140-6736(96)07088-2. - DOI - PubMed
    1. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009;91:2556–2561. doi: 10.2106/JBJS.H.01774. - DOI - PubMed
    1. Chan SS, Rosenberg ZS, Chan K, Capeci C. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. AJR Am J Roentgenol. 2010;194:1581–1586. doi: 10.2214/AJR.09.3588. - DOI - PubMed
    1. Chrischilles EA, Dasbach EJ, Rubenstein LM, Cook JR, Tabor HK, Black DM. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Osteoporos Int. 2001;12:654–660. doi: 10.1007/s001980170065. - DOI - PubMed

MeSH terms

Substances